Safety and efficacy of low-dose paclitaxel utilizing the cobra-P drug-eluting stent system with a novel biodegradable coating in de novo coronary lesions: the PLUS-ONE first-in-man study.

Background: The Cobra-P drug-eluting stent (DES) system consists of cobalt chromium alloy with bio-absorbable siloxane sol-gel matrix coating that elutes low dose paclitaxel within 6 months. The aim of this first-in-man trial was to evaluate the safety and performance of 2 doses of the Cobra-P DES.

Methods: A total of 60 lesions (54 patients) were sequentially assigned to 2 different paclitaxel doses: group A (3.

Percutaneous edge-to-edge mitral valve repair: 2-year follow-up in the first human case.

We report the first-in-human mitral valve repair using percutaneous technology that creates a "surgical-like" edge-to-edge repair. A catheter-delivered clip was introduced transseptally from the femoral vein, advanced through the mitral orifice, retracted to grasp the leaflets, and detached to create a functional double-orifice valve. The patient had an uncomplicated post-procedural course.

Catheter-based approach to mitral regurgitation.

Mitral Regurgitation (MR) is a common medical problem. MR is also a prognostic factor; patients with severe symptomatic MR have a poor prognosis with an annual mortality rate of 5% without surgical intervention. An anatomic understanding of the normal and regurgitant mitral valve is essential in order to evaluate appropriately the severity and impact of MR.